Journal · Updated 2026-08-11
TMates Review 2026: The $158 Headline and the 78% Spread Behind It
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
TMates prices in two ladders with the market's widest term spread. Semaglutide: one fifty-eight a month on the twelve-month plan against two forty-nine month-to-month. Tirzepatide: one sixty-seven committed against two ninety-seven monthly — a seventy-eight percent gap that tops our Teaser Index. Medication and visits are included at both tiers; status is reported from 2026 third-party captures. The read: the committed rates are genuinely mid-competitive (one sixty-seven tirzepatide sits between the one thirty-nine floor and Henry's one seventy-nine), while the monthly rates are flexibility-tier ceilings that exist to sell the commitment — which makes TMates a committed buyer's program whose headline should always be quoted with its term attached.
Structure and the watch-flags
The included bundle — medication, provider visits — is the standard all-in shape, with a hands-on clinical positioning in its marketing. Two flags from our records: the headline figure is the semaglutide twelve-month rate, so a tirzepatide shopper reading "$158" is two corrections away from their real number (different molecule, then different term — one sixty-seven committed, two ninety-seven monthly); and the pharmacy partner is not publicly named, so the standard intake extraction and fifteen-minute verification apply. Exit mechanics on the twelve-month term belong in writing before enrollment, as at every committed program.
Verdict
On the committed basis TMates is respectable: one sixty-seven tirzepatide beats Henry's one seventy-nine flat and loses to bmiMD/NexLife's one thirty-nine; one fifty-eight semaglutide loses to the ninety-nine floor by a wide margin. On the monthly basis it isn't a contender at either molecule — two forty-nine and two ninety-seven are among the highest flexibility prices we track. The fit: a buyer certain of the year who values the clinical-touch positioning and confirms the pharmacy; everyone else finds the same commitment cheaper at bmiMD, or the same flexibility far cheaper at the no-commitment tier.
Questions people ask
How much does TMates cost?
Semaglutide: $158/month on the twelve-month plan, $249 month-to-month. Tirzepatide: $167 committed, $297 monthly — a 78% spread, the widest in our index. Medication and visits included at both tiers; reported status from 2026 captures.
Is TMates' $158 price for tirzepatide?
No — $158 is the semaglutide twelve-month rate. Tirzepatide runs $167 on the same commitment and $297 month-to-month. Confirm your molecule and term at checkout; the headline requires both corrections.
Is TMates cheaper than Henry Meds?
Only with the commitment: $167 committed tirzepatide beats Henry's $179 flat, but Henry's $179 is month-to-month — TMates' comparable monthly rate is $297. On semaglutide, Henry's $179 beats TMates' $249 monthly and loses to its $158 committed.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.